B.S., Jinlin Medical college, 2014 Clinical Medicine
M.S., Harbin Medical University, 2017 Advisor: Prof. Hongyu Kuang
Ph.D., Harbin Medical University, 2021 Advisor: Prof. Hongyu Kuang
Xinyang Yu, et al. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy. Eur J Pharmacol 2019, 864, 172715.
Xinyang Yu, et al. Long noncoding RNA MIAT regulates primary human retinal pericyte pyroptosis by modulating miR-342-3p targeting of CASP1 in diabetic retinopathy. Exp Eye Res 2021, 202, 108300.
The main direction of her previous research was the study of the pathogenesis of diabetes and its complications, and to explore the potential molecular mechanisms of emerging drugs. The current research direction is tumor immunotherapy based on supramolecular materials.